EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Challenge of Anticoagulation in Liver Cirrhosis

Julia Carolin Eichholz, Heiner Wedemeyer, Benjamin Maasoumy

Visceral Medicine · 2023 · 39 (6) · 169-176

DOI: 10.1159/000535438 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Visceral Medicine, online erschienen am 21.12.2023. Verfasst von Julia Carolin Eichholz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Advanced liver diseases are characterized by a number of changes in the hemostatic system. Due to the occurrence of bleeding events in patients with liver cirrhosis, there seems to be a hesitance to the administration of anticoagulant medications. This review summarizes challenges, recommendations, and current developments of anticoagulation in the cirrhotic patient. Summary: The risk of thrombotic events in patients with liver cirrhosis is at least as high as in patients with healthy liver function if not even higher. Standard laboratory markers do not truly reflect the complexity of changes that take place in the coagulative system and therefore cannot be used as a reference for risk of thrombosis or hemorrhage. Potential options for anticoagulant therapy are heparins, vitamin K antagonists, and direct-acting oral anticoagulants which come with differences in safety, application, possible side effects, and data availability for the patient cohort. Key Message: The administration of anticoagulation can be beneficial in patients with liver disease if the indication is present and bleeding prophylaxis has been established. Direct-acting oral anticoagulants appear to be a promising new approach with many improvements compared to conventional substances. Nevertheless, there is a need for further data and prospective trials on the use in patients with liver cirrhosis.

Schlagwörter

Stichwörter der Autor:innen

AnticoagulationBleedingLiver cirrhosisTherapyThrombosis

Autor:innen und Institutionen

  • Department of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
  • German Centre for Infection Research (DZIF), Hannover-Braunschweig, Hannover, Germany.
  • Excellence Cluster Resist, Hannover Medical School, Hannover, Germany.
  • D-SOLVE Consortium, Hannover, Germany.
  • Center for Individualized Infection Medicine (CIIM), Hannover, Germany.

Zitieren

APA

Eichholz, J. C., Wedemeyer, H., & Maasoumy, B. (2023). The Challenge of Anticoagulation in Liver Cirrhosis. Visceral Medicine, 39(6), 169-176. https://doi.org/10.1159/000535438

Vancouver

Eichholz JC, Wedemeyer H, Maasoumy B. The Challenge of Anticoagulation in Liver Cirrhosis. Visceral Medicine. 2023;39(6):169-176. doi:10.1159/000535438

BibTeX
@article{Eichholz2023,
  author = {Eichholz, Julia Carolin and Wedemeyer, Heiner and Maasoumy, Benjamin},
  title = {The Challenge of Anticoagulation in Liver Cirrhosis},
  journal = {Visceral Medicine},
  year = {2023},
  volume = {39},
  number = {6},
  pages = {169--176},
  doi = {10.1159/000535438}
}
Kostenlos starten →